LAUSANNE, Switzerland, Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:10 a.m. ET.A webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ...

Core Insights - Akeso, Inc. reported record commercial sales in China and significant global advancements in its oncology and autoimmune pipelines for the first half of 2025, driven by its "IO 2.0 + ADC 2.0" strategy [2][11][34] - The company has established itself as a leader in immuno-oncology bispecific antibodies, particularly with cadonilimab and ivonescimab, which are being evaluated in numerous global clinical trials [5][6][9][22] - Akeso's non-oncology portfolio is also expanding, with recent product launches and ongoing developments in autoimmune diseases, contributing to overall growth [10][31][36] Financial Performance - Total commercial sales increased by 49.20%, from RMB 939.4 million in the first half of 2024 to RMB 1,401.6 million in the first half of 2025, reflecting robust market penetration [11] - Research and development expenses for the same period were RMB 731.2 million, with total cash and equivalents amounting to RMB 7,138.4 million as of June 30, 2025 [12] Oncology Pipeline - Ivonescimab and cadonilimab are being evaluated in 23 registrational/Phase III trials and over 20 Phase II studies globally, with ivonescimab demonstrating statistically significant overall survival benefits in its trials [6][8][18] - Cadonilimab has received approvals for multiple indications, including first-line treatments for cervical and gastric cancers, addressing significant unmet needs in immunotherapy [22][23][25] Non-Oncology Pipeline - The company has launched ebdarokimab and ebronucimab, with upcoming launches for gumokimab and manfidokimab, enhancing its competitive position in the autoimmune sector [10][31][35] - Akeso's innovative candidates targeting neurological diseases and other chronic conditions are also progressing through development [32][36] Strategic Initiatives - Akeso is advancing a next-generation pipeline of bispecific ADCs and dual-payload ADCs, aiming to redefine the oncology treatment landscape [27][29] - The company is open to strategic collaborations to enhance its global reach and maximize therapeutic value [26]

Analyst's Disclosure:I/we have a beneficial long position in the shares of ADC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any inv ...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

Core Viewpoint - Dividend growth stocks may not be the most exciting investments but are designed to build growing income for investors [1] Group 1: Investment Strategy - The focus is on high-quality and reliable dividend growth ideas that provide stability and long-term wealth creation [1] - The service also includes ideas for writing options to further enhance investors' income [1] Group 2: Membership Benefits - Membership provides access to a portfolio, watchlist, and live chat [2] - Members receive early access to all publications and exclusive articles not available elsewhere [2]

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial . If you wanna watch money disappear, go buy a boat. If you wanna see it double in a couple years, buy some land. If you're gonna bet it all, all I can say is football Analyst's Disclosure:I/we have a beneficial long position in the shares of CP, UNP, AM, REXR either through stoc ...

Core Insights - The U.S. FDA has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren) for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [1][3][5] - Iza-bren is a bispecific antibody-drug conjugate targeting both EGFR and HER3, developed by SystImmune and Bristol Myers Squibb [2][7] - The BTD highlights the potential of iza-bren to address significant unmet clinical needs for patients who have progressed after existing treatments [3][5] Company Overview - SystImmune is a clinical-stage biopharmaceutical company focused on innovative cancer treatments, utilizing bi-specific and multi-specific antibodies, as well as antibody-drug conjugates [8][9] - Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering and delivering innovative medicines for serious diseases [10] Clinical Data - The FDA's decision was based on data from three ongoing clinical trials, indicating improved efficacy and manageable safety for iza-bren in patients with EGFR-mutant NSCLC [4][6] - NSCLC accounts for approximately 80% of lung cancer cases, with a significant portion of patients harboring activating EGFR mutations, highlighting the need for new therapies [6]

Core Viewpoint - Agree Realty (NYSE: ADC) is recognized as one of the largest net lease REITs with a strong reputation in the market [1]. Group 1 - The company has previously been rated a 'hold' regarding its preferred shares, indicating a cautious approach to investment in this area [1]. - A small long position has been re-established, with plans to increase this position in the coming weeks and months, suggesting a positive outlook for future investment [2].

Group 1 - Hoya Capital Research & Index Innovations is an affiliate of Hoya Capital Real Estate, providing investment advisory services focused on publicly traded securities in the real estate industry [2] - The firm offers non-advisory services including market commentary, research, and index administration [2] - The commentary published by Hoya Capital is intended for informational and educational purposes only, and does not constitute investment, tax, or legal advice [2] Group 2 - Hoya Capital Real Estate is based in Rowayton, Connecticut, and serves ETFs, individuals, and institutions [2] - The firm emphasizes that past performance is not indicative of future results, and any market data quoted represents past performance [3] - Hoya Capital and its affiliates may hold positions in securities or funds discussed in their commentary [2]

Perspective: "Do not store up for yourselves treasures on earth, where moth and rust destroy, and where thieves break in and steal. But store up for yourselves treasures in heaven, where neither moth nor rust destroys, and where thieves do not break in or steal; for where your treasure is, there your heart will be also ... For what will it profit a man if he gains the whole world and forfeits his soul?" ~ Jesus (Matthew 6:19-21; 16:26) Learn more Samuel Smith has a diverse background that includes being lea ...